TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38326352

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 38326432

Group type: EXPERIMENTAL
Intervention: Psilocybin (25 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Diphenhydramine (50 mg)
Number of subjects: 11
Study: 38326493

Group type: EXPERIMENTAL
Intervention: School social intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Typical school programming (services-as-usual [SAU])
Number of subjects: 90
Study: 38326577

Group type: EXPERIMENTAL
Intervention: Holmium-166 radioembolization
Number of subjects: 37
Study: 38326734

Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Training (HIRT) for 16 months, twice weekly
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (non-training)
Number of subjects: 31
Study: 38326736

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) group
Number of subjects: 136

Group type: COMPARATOR
Intervention: Sinus rhythm (SR) group
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Both AF and SR groups
Number of subjects: 136
Study: 38326814

Group type: EXPERIMENTAL
Intervention: e-mpodera vCoP
Number of subjects: 185
Study: 38326832

Group type: EXPERIMENTAL
Intervention: iHEAL intervention delivered by Registered Nurses over 6-7 months
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: iHEAL intervention
Number of subjects: 331

Group type: COMPARATOR
Intervention: Control (community service information)
Number of subjects: 331
Study: 38326847

Group type: EXPERIMENTAL
Intervention: Emotion Detectives In-Out program (blended version of the Unified Protocol for Children)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Coping Cat program (evidenced-based group intervention for children with anxiety disorders)
Number of subjects: 138
Study: 38326858

Group type: EXPERIMENTAL
Intervention: Etidronate 20 mg/kg administered daily in capsules for two weeks on followed by ten weeks off for 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered daily in capsules for two weeks on followed by ten weeks off for 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38326920

Group type: EXPERIMENTAL
Intervention: Human serum albumin 20% 100 mL over 15 min
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline 500 mL
Number of subjects: 50
Study: 38327509

Group type: COMPARATOR
Intervention: Pre-pandemic levels
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: During the pandemic
Number of subjects: 1843
Study: 38327730

Group type: EXPERIMENTAL
Intervention: Medication-free treatment
Number of subjects: 183

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 183
Study: 38327981

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38328552

Group type: EXPERIMENTAL
Intervention: Two-part mechanotherapy (Flyte) for 12 weeks
Number of subjects: 144

Group type: COMPARATOR
Intervention: Part 1 therapy for 6 weeks followed by full therapy
Number of subjects: 144
Study: 38328709

Group type: EXPERIMENTAL
Intervention: inetetamab (loading dose of 8 mg/kg and subsequent doses of 6 mg/kg intravenously once every 3 weeks), pyrotinib (400 mg orally once daily), and vinorelbine (60 mg/m2 weekly)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: inetetamab, pyrotinib, and oral vinorelbine
Number of subjects: 30
Study: 38328752

Group type: EXPERIMENTAL
Intervention: Minimally invasive sacroiliac joint fusion
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 63
Study: 38328915

Group type: EXPERIMENTAL
Intervention: New hypertension diagnosis
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Achieved target BP control
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Systolic BP change
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Diastolic BP change
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Achieving BP control
Number of subjects: 323

Group type: COMPARATOR
Intervention: Undiagnosed hypertension
Number of subjects: 323
Study: 38328938

Group type: EXPERIMENTAL
Intervention: BCG vaccinated children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonvaccinated children
Number of subjects: 0
Study: 38329108

Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P
Number of subjects: 261

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 261
Study: 38329117

Group type: EXPERIMENTAL
Intervention: Presence of mediators in EDs
Number of subjects: 50429

Group type: COMPARATOR
Intervention: Control group (no mediators)
Number of subjects: 50429
Study: 38329130

Group type: EXPERIMENTAL
Intervention: Early-treated individuals (N = 12)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Chronic-treated participants (N = 33)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Chronic-treated individuals (N = 33)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study: 38329148

Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg, up to 25 mg)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study: 38329153

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 7 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 88
Study: 38329180

Group type: EXPERIMENTAL
Intervention: Pre-pandemic group (n=1166)
Number of subjects: 2938

Group type: EXPERIMENTAL
Intervention: Pandemic group (n=979)
Number of subjects: 2938

Group type: EXPERIMENTAL
Intervention: Pandemic group
Number of subjects: 2938

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 2938
Study: 38329222

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 311
Study: 38329404

Group type: EXPERIMENTAL
Intervention: Short-time cardiac MRI in breast cancer participants undergoing chemotherapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Short-time cardiac MRI in healthy female controls
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Short-time cardiac MRI in breast cancer participants undergoing immediate chemotherapy
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Short-time cardiac MRI in breast cancer participants undergoing remote chemotherapy
Number of subjects: 98
Study: 38329405

Group type: EXPERIMENTAL
Intervention: Periaortic adipose tissue attenuation in patients with abdominal aortic aneurysms (both asymptomatic and symptomatic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls without aneurysms
Number of subjects: 0
Study: 38329507

Group type: EXPERIMENTAL
Intervention: Adjuvant (super-)selective infusion of holmium-166 microspheres after radiofrequency ablation
Number of subjects: 12
Study: 38329642

Group type: EXPERIMENTAL
Intervention: mCIMT + real iTBS
Number of subjects: 17

Group type: COMPARATOR
Intervention: mCIMT + sham iTBS
Number of subjects: 17

Group type: COMPARATOR
Intervention: mCIMT alone
Number of subjects: 17
Study: 38329646

Group type: EXPERIMENTAL
Intervention: 0.5 mg ocedurenone administered orally
Number of subjects: 2
Study: 38329716

Group type: EXPERIMENTAL
Intervention: Futibatinib 20 mg once daily
Number of subjects: 469
Study: 38329728

Group type: EXPERIMENTAL
Intervention: GZ17-6.02
Number of subjects: 0
Study: 38329732

Group type: EXPERIMENTAL
Intervention: Paclitaxel treatment in breast cancer cohorts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing phase II clinical trial for glioblastoma patients
Number of subjects: 0
Study: 38329737

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy in combination with radiotherapy (IC-RT) group
Number of subjects: 383

Group type: COMPARATOR
Intervention: Induction chemotherapy combined with chemoradiotherapy (IC-CCRT) group
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 383
Study: 38329745

Group type: EXPERIMENTAL
Intervention: MW032
Number of subjects: 708

Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 708
Study: 38329746

Group type: EXPERIMENTAL
Intervention: HBOT (30 to 40 sessions over 6 to 8 weeks)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control (no HBOT)
Number of subjects: 189
Study: 38329757

Group type: EXPERIMENTAL
Intervention: Supervised multicomponent exercise program during hospitalization and health education on how to exercise at home with telephone counseling during follow-up.
Number of subjects: 260

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 260
Study: 38329779

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) consisting of information on the risk of inappropriate use and individualized advice on how to reduce use.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 5
Study: 38329790

Group type: EXPERIMENTAL
Intervention: Chinese electroacupuncture (30 minutes per session, 2 sessions per week for 8 weeks)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Chinese electroacupuncture
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (1 pair of electrically charged needles on the head)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 168
Study: 38329996

Group type: EXPERIMENTAL
Intervention: My Choice-My Way! leaving care program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 0
Study: 38330026

Group type: EXPERIMENTAL
Intervention: Elastic adhesive tape
Number of subjects: 768

Group type: COMPARATOR
Intervention: Fixation cord with PVC sheath
Number of subjects: 768
Study: 38330045

Group type: EXPERIMENTAL
Intervention: Same-day initiation (SDI) of antiretroviral therapy (ART)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TB results first approach (ART only after active TB has been confirmed or refuted)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Same-day initiation (SDI) of ART
Number of subjects: 0
Study: 38330169

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38330179

Group type: EXPERIMENTAL
Intervention: Mitapivat (M/M arm)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mitapivat (P/M arm after week 24)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mitapivat (P/M arm)
Number of subjects: 40
Study: 38330285

Group type: EXPERIMENTAL
Intervention: Apitegromab 20 mg/kg alone or in combination with nusinersen (Cohort 1)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Apitegromab 20 mg/kg combined with nusinersen (Cohort 2)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Apitegromab 2 mg/kg combined with nusinersen (Cohort 3)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Apitegromab 20 mg/kg combined with nusinersen (Cohort 3)
Number of subjects: 58
Study: 38330306

Group type: EXPERIMENTAL
Intervention: Responsive parenting (RP) intervention
Number of subjects: 212

Group type: COMPARATOR
Intervention: Safety control condition
Number of subjects: 212
Study: 38330355

Group type: EXPERIMENTAL
Intervention: Maternal severe mental illness (SMI)
Number of subjects: 93

Group type: COMPARATOR
Intervention: No maternal diagnosis
Number of subjects: 93
Study: 38330357

Group type: EXPERIMENTAL
Intervention: rCSP/GLA-LSQ 10 µg × 3
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: rCSP/GLA-LSQ 30 µg × 3
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: rCSP/GLA-LSQ 60 µg × 3
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: rCSP/GLA-LSQ 60 µg × 2
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: rCSP 30 µg alone × 3
Number of subjects: 49

Group type: COMPARATOR
Intervention: Infectivity controls
Number of subjects: 49
Study: 38330368

Group type: EXPERIMENTAL
Intervention: BSHAPE intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 144
Study: 38330377

Group type: EXPERIMENTAL
Intervention: RKP00156 vaginal tablet (25 mg dose)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: RKP00156 vaginal tablet (10 mg or 50 mg doses)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: RKP00156 vaginal tablet
Number of subjects: 86
Study: 38330380

Group type: EXPERIMENTAL
Intervention: Surgical debulking of bulky or multiple lymph nodes before concurrent chemoradiation therapy (CCRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent chemoradiation therapy (CCRT)
Number of subjects: 0
Study: 38330409

Group type: EXPERIMENTAL
Intervention: Daily glucose monitoring
Number of subjects: 197

Group type: COMPARATOR
Intervention: Every-other-day glucose monitoring
Number of subjects: 197
Study: 38330866

Group type: EXPERIMENTAL
Intervention: Preoperative physiotherapy intervention
Number of subjects: 14

Group type: COMPARATOR
Intervention: No preoperative physiotherapy intervention
Number of subjects: 14
Study: 38330942

Group type: EXPERIMENTAL
Intervention: ADG106 (5.0 mg/kg dose level)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ADG106 (10.0 mg/kg dose level)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ADG106
Number of subjects: 62
Study: 38330975

Group type: EXPERIMENTAL
Intervention: Onradivir 200 mg twice per day
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Onradivir 400 mg twice per day
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Onradivir 600 mg once per day
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: All onradivir groups
Number of subjects: 172
Study: 38330980

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 2387

Group type: COMPARATOR
Intervention: Conventional in-vitro fertilisation (IVF)
Number of subjects: 2387
Study: 38330987

Group type: EXPERIMENTAL
Intervention: Survodutide 0.6 mg
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Survodutide 2.4 mg
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Survodutide 3.6 mg
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Survodutide 4.8 mg
Number of subjects: 387

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Survodutide
Number of subjects: 387
Study: 38330988

Group type: EXPERIMENTAL
Intervention: Semaglutide 2·4 mg
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 38331027

Group type: EXPERIMENTAL
Intervention: Intervention period (after implementation of checklist)
Number of subjects: 1108
Study: 38331204

Group type: EXPERIMENTAL
Intervention: Autonomous AI-based CADx optical diagnosis of diminutive polyps
Number of subjects: 467

Group type: COMPARATOR
Intervention: AI-assisted human (AI-H) optical diagnosis of diminutive polyps
Number of subjects: 467
Study: 38331348

Group type: EXPERIMENTAL
Intervention: L-carnitine syrup (100 mg/kg/d) for 15 days
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo for 15 days
Number of subjects: 98
Study: 38331400

Group type: EXPERIMENTAL
Intervention: UPA15 15 mg once daily
Number of subjects: 639

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 639
Study: 38331453

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38331586

Group type: EXPERIMENTAL
Intervention: Non-fatal overdose experience
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Prior overdose experience
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Substance(s) used during worst overdose experience
Number of subjects: 771

Group type: COMPARATOR
Intervention: Alcohol and cannabis group
Number of subjects: 771

Group type: COMPARATOR
Intervention: Alcohol with other substance(s) group
Number of subjects: 771

Group type: COMPARATOR
Intervention: Other substance(s) only group
Number of subjects: 771
Study: 38331709

Group type: EXPERIMENTAL
Intervention: Headache presence
Number of subjects: 7832
Study: 38331793

Group type: EXPERIMENTAL
Intervention: Distal transradial access (dTRA)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Conventional transradial access (TRA)
Number of subjects: 726
Study: 38331799

Group type: EXPERIMENTAL
Intervention: Olfactory disorders group (ODG)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normosmic group (NG)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Self-perceived olfactory evaluation in NG
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Self-perceived olfactory evaluation in ODG
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Psychophysical tests and self-perceived olfactory evaluations
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Anxiety and depression dimensions
Number of subjects: 56
Study: 38331822

Group type: EXPERIMENTAL
Intervention: Health promotion intervention program for childcare teachers, including a 6-month training program on healthy lifestyles (diet, sleep, physical activity, sedentary behavior)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 344
Study: 38331891

Group type: EXPERIMENTAL
Intervention: Imidazole propionate (ImP) levels in chronic HF patients
Number of subjects: 166

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Markers of intestinal permeability and systemic inflammation
Number of subjects: 166
Study: 38331900

Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycaemia
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normoglycaemia
Number of subjects: 32
Study: 38332008

Group type: EXPERIMENTAL
Intervention: InTandem (autonomous neurorehabilitation system)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38332403

Group type: EXPERIMENTAL
Intervention: Signal intensity gradient (SIG) from TOF-MRA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase contrast magnetic resonance (PC-MR)
Number of subjects: 0
Study: 38332428

Group type: EXPERIMENTAL
Intervention: Cirrhosis patients
Number of subjects: 107
Study: 38332436

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Guselkumab (GUS)
Number of subjects: 1027
Study: 38332440

Group type: EXPERIMENTAL
Intervention: Bundled fecal immunochemical testing (FIT) and social determinants of health (SDOH) screening
Number of subjects: 34588

Group type: COMPARATOR
Intervention: Control group (no bundled FIT-SDOH screening)
Number of subjects: 34588
Study: 38332460

Group type: EXPERIMENTAL
Intervention: Dolutegravir-based ART
Number of subjects: 689

Group type: COMPARATOR
Intervention: Emtricitabine and tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide fumarate (TAF)
Number of subjects: 689
Study: 38332651

Group type: EXPERIMENTAL
Intervention: Hydroxyurea at maximum tolerated dose (MTD)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Hydroxyurea at MTD
Number of subjects: 635

Group type: COMPARATOR
Intervention: Pre-treatment
Number of subjects: 635

Group type: COMPARATOR
Intervention: Fixed-dose hydroxyurea
Number of subjects: 635

Group type: COMPARATOR
Intervention: Dose escalation hydroxyurea
Number of subjects: 635
Study: 38332984

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) for 20 minutes at 2 mA for 10 daily sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training combined with tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 38333020

Group type: EXPERIMENTAL
Intervention: Callergin (iota-carrageenan nasal spray)
Number of subjects: 42

Group type: COMPARATOR
Intervention: VisAlpin (comparator product)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 42
Study: 38333368

Group type: EXPERIMENTAL
Intervention: Participants with clinically relevant fatigue at baseline
Number of subjects: 3038

Group type: EXPERIMENTAL
Intervention: Participants with cognitive deficits
Number of subjects: 3038

Group type: EXPERIMENTAL
Intervention: Risk factors for non-recovery from fatigue
Number of subjects: 3038

Group type: EXPERIMENTAL
Intervention: Risk factors for cognitive non-recovery
Number of subjects: 3038

Group type: COMPARATOR
Intervention: SARS-CoV-2 reinfection
Number of subjects: 3038
Study: 38333728

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality plus ERAS protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: ERAS protocol alone
Number of subjects: 0
Study: 38333889

Group type: EXPERIMENTAL
Intervention: GAD65Ab positivity
Number of subjects: 100
Study: 38333967

Group type: EXPERIMENTAL
Intervention: ACLR+LEAP augmentation
Number of subjects: 253

Group type: COMPARATOR
Intervention: ACLR alone
Number of subjects: 253
Study: 38334147

Group type: EXPERIMENTAL
Intervention: Oral methotrexate (5 mg/m²)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Methotrexate plus intra-articular glucocorticoid (IAGC) therapy
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 575

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575
Study: 38334413

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine 0.1% solution
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Vehicle group (control)
Number of subjects: 1162
Study: 38334470

Group type: EXPERIMENTAL
Intervention: Low-dose positron emission mammography (PEM) with up to 185 MBq of fluorine 18-labeled fluorodeoxyglucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 0
Study: 38334499

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-BLYS agents, novel calcineurin inhibitors, CD20 blockade, and antiinterferon agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Algorithm for induction and maintenance treatment of lupus nephritis
Number of subjects: 0
Study: 38334943

Group type: EXPERIMENTAL
Intervention: Patients with gene mutations (including SPINK1, PRSS1, CTRC, CFTR)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Patients without gene mutations
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Patients with gene mutations (including SPINK1)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Patients with CP-susceptibility gene mutations
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Patients with SPINK1 mutations
Number of subjects: 160
Study: 38334953

Group type: EXPERIMENTAL
Intervention: ALD group
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: 24-hour urinary sucralose
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: 24-hour sucralose/lactulose ratio
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Aspirin challenge
Number of subjects: 178

Group type: COMPARATOR
Intervention: Five-hour urinary lactulose/mannitol ratio
Number of subjects: 178